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: (1) loss of function due to decreased C9orf72 expression, (2) gain of function due to RNA foci that sequester critical proteins, and (3) gain of function due to expression of dipeptide repeat proteins encoded by the expansion.
The loss-of-function hypothesis is based on observations of reduced C9orf72 levels in expansion carriers, mediated at least in part through epigenetic mechanisms, including increases in DNA methylation within the C9orf72 promoter. [2] [3] [4] [5] For most genes, DNA methylation reduces gene expression, and this is true for C9orf72. 2, 3 While increased DNA methylation is observed in C9orf72 carriers, it has been unclear whether it is protective (by reducing gain-of-function effects) or detrimental (by causing loss of function). In this issue of Neurology ® , McMillan et al. 6 present data suggesting a protective effect of C9orf72 DNA methylation.
The authors studied 20 individuals with C9orf72 expansions. Prior studies showed that in controls and patients with FTD without C9orf72 expansions, there is little DNA methylation in this region of C9orf72.
2,5 By contrast, in C9orf72 expansion carriers, the DNA methylation rate for this locus ranged up to almost 40%. McMillan et al. 6 first examined the relationship between C9orf72 methylation and regional gray matter volumes by structural MRI. Those with more methylation had less atrophy in several brain regions. Next they examined the relationship between DNA methylation and neuronal loss. Greater C9orf72 methylation was associated with less neuron loss in both hippocampus and frontal cortex. 6 Finally, and perhaps most interestingly, the authors examined longitudinal imaging and cognitive data over about 1 year. Consistent with the crosssectional data, more C9orf72 methylation was associated with slower rates of volume loss by MRI and verbal recall decline on neuropsychological testing. 6 These findings provide evidence that the DNA methylation of C9orf72 is protective, not detrimental, in patients with ALS or FTD due to C9orf72 expansions.
The study is consistent with other recent findings from the same group that higher levels of C9orf72 DNA methylation are associated with fewer RNA foci and dipeptide repeat aggregates, 3 plus longer disease course and later death. 4 Together, these findings indicate that epigenetic mechanisms counteract genetics at C9orf72, with DNA methylation suppressing effects of the repeat expansion. Combined with reports that reducing C9orf72 in mice using antisense oligonucleotides does not have apparent toxicity 7 and other similar findings, these data may spell the beginning of the end for the loss-of-function hypothesis of C9orf72 pathogenesis.
While the study of McMillan et al. 6 has several strengths, including the combination of neuroimaging and neuropathologic analyses and a longitudinal component, it also has limitations. This is a relatively small study, and the participants were an admixture of different clinical phenotypes, including ALS, behavioral variant FTD, FTD-ALS, and the nonfluent/agrammatic variant of primary progressive aphasia. While an exploratory analysis did not find differences in methylation rates among clinical subtypes, the sample sizes are too small to be definitive, and it remains possible that the observed differences in regional volumes and cell counts could be driven by differential segregation of certain clinical phenotypes toward higher (or lower) methylation rates.
Another concern regarding this study is that the neuroimaging and longitudinal analyses were based on analysis of C9orf72 methylation in blood, rather than in brain tissue. However, for many genes, levels of DNA methylation in blood correlate with levels in brain, and this holds true for C9orf72. 4 The fact that DNA methylation measurements from blood correlate with multiple disease measures poses an opportunity for an easily accessible biomarker.
How might epigenetics come into play in clinical neurology? Cancer biology, where understanding epigenetic dysregulation of tumor suppressor genes and oncogenes has facilitated both biomarker discovery and development of novel therapeutics, may provide a useful analogy. Epigenetic biomarkers have been identified in several malignancies and help predict cancer incidence and survival rates in vulnerable populations. 8 Likewise, epigenetics-based therapeutics have been Food and Drug Administrationapproved for at least 2 cancers, refractory cutaneous T-cell lymphoma and myelodysplastic syndrome. These therapies prolong survival and improve quality of life, and other promising new drugs are in the pipeline. 9 Neuroepigenetics is a younger field and its clinical potential is less well-defined. However, several studies have linked specific epigenetic alterations to Alzheimer disease, Parkinson disease, ALS, and epilepsy. In cases where these differences can be detected in blood, epigenetic biomarkers could be used to identify vulnerable populations before disease onset or considered alongside other risk factors and incorporated into treatment decisions. Preclinically, considerable evidence also suggests potential for epigenetics-based therapeutics in neurodegenerative disorders, including improved cognitive function following treatment with drugs that modulate the epigenome. 10 Although biomarker applications for neuroepigenetics are probably closer to fruition than treatments are, discoveries of an epigenetic role in the etiology of these disorders present a new avenue for therapeutics.
If C9orf72 hypermethylation in FTD and ALS is neuroprotective, an obvious therapeutic strategy for mutation carriers would be to boost DNA methylation at C9orf72. Supplementation with the methyl donor, S-adenosyl methionine, is an established but nonspecific approach to increasing DNA methylation. However, it could have unwanted off-target effects. Such lack of genetic specificity demonstrates a key pitfall of current epigenetically targeted treatments, but a rapidly emerging set of epigenetic engineering techniques is beginning to allow the necessary genetic specificity, at least in experimental settings. These tools utilize the inherent DNA sequence recognition capacity of bacterial CRISPR (clustered regularly interspaced short palindromic repeats) or TALE (transcription activator-like effector) systems to direct epigenetic modifiers to targeted sites in DNA, and are currently being applied to enable custom reorganization of epigenetic marks in animal models. 11 Although these approaches are at best many years from clinical applications, such revolutionary advances in technology highlight the enticing potential for epigenetics-based therapeutics in neurologic disease.
